Health
Novo Signs $2 Billion Deal With United Labs for Obesity Drug
This article is for subscribers only.
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker’s latest move to refill its pipeline of experimental treatments.
Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different mechanisms in an effort to treat obesity as well as diabetes and other diseases, the companies said Monday. Novo agreed to pay as much as $1.8 billion if the drug reaches certain development and sales goals.